Amicus gears up to launch Pompe disease combination therapy in the UK
Amicus’ Pombiliti and Opfolda received approval from the UK MHRA through the Innovative Licensing and Access Pathway.
Amicus’ Pombiliti and Opfolda received approval from the UK MHRA through the Innovative Licensing and Access Pathway.
What's Your Reaction?
